Market-Moving News for May 1 st
$PALI
$SBUX
$TGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Restaurants
Consumer Discretionary
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/15/2024 | $115.00 | Outperform | RBC Capital Mkts | |
| 11/13/2024 | $84.00 → $77.00 | Neutral → Sell | Redburn Atlantic | |
| 10/29/2024 | $50.00 | Buy | TD Cowen | |
| 10/17/2024 | $100.00 → $115.00 | Buy | BTIG Research | |
| 10/17/2024 | $98.00 → $115.00 | Overweight | Morgan Stanley | |
| 9/26/2024 | $92.00 → $115.00 | Mkt Perform → Outperform | Bernstein | |
| 9/24/2024 | $80.00 → $76.00 | Hold → Underperform | Jefferies | |
| 9/18/2024 | $112.00 → $118.00 | Buy | BofA Securities |
4 - STARBUCKS CORP (0000829224) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:
Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ET NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with recent company developments and provided an update on 2024 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, "The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are excited to
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com
Results Reflect Challenged Customer Experience; Management is Developing a Plan to Get Back to Starbucks Q4 Consolidated Net Revenues Down 3% to $9.1 Billion; Frequency Declined Across Customer Segments Q4 GAAP and Non-GAAP EPS of $0.80; Traffic Focused Investments Further Pressured Results Q4 Active U.S. Starbucks® Rewards Membership Totals 33.8 Million, Up 4% Over Prior Year Starbucks Corporation (NASDAQ:SBUX) today reported financial results for its 13-week fiscal fourth quarter and 52-week fiscal year ended September 29, 2024. GAAP results in fiscal 2024 and fiscal 2023 include items that are excluded from non-GAAP results. Please refer to the reconciliation of GAAP measures to non-GAA
Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn's disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preclinical results for PALI-2108, a novel local PDE4 inhibitor prodrug. In recent studies using the Dextran Sulfate Sodium (DSS) colitis mouse model, PALI-2108 demonstrated a dose-dependent effect on key fibrotic pathways, underscoring its
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The Company's growth between fiscal years 2020 to 2023 was fueled by BRIUMVI® revenues, which was approved to treat adult individuals with relapsing forms of multiple sclerosis in December of 2022. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, "We are proud to be recognized as the fastest-growing c
Presentation to highlight advances in fibrostenotic Crohn's Disease and the potential of localized PDE4 inhibition Carlsbad, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic disease, today announced that it has been invited to present at the 8th Annual Antifibrotic Drug Development (AFDD) Summit, being held November 19-21, 2024, in Boston, MA. Details of the presentation details are as follows: Title: Detailing Characteristics of Fibrostenotic Crohn's Disease Biology
4 - STARBUCKS CORP (0000829224) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
FWP - PALISADE BIO, INC. (0001357459) (Subject)
8-K - STARBUCKS CORP (0000829224) (Filer)
S-1/A - PALISADE BIO, INC. (0001357459) (Filer)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SC 13G - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
RBC Capital Mkts resumed coverage of Starbucks with a rating of Outperform and set a new price target of $115.00
Redburn Atlantic downgraded Starbucks from Neutral to Sell and set a new price target of $77.00 from $84.00 previously
TD Cowen initiated coverage of TG Therapeutics with a rating of Buy and set a new price target of $50.00
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Below are some instances of options activity happening in the Consumer Discretionary sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BABA CALL TRADE BULLISH 08/02/24 $79.00 $27.0K 2.4K 1.7K SBUX CALL TRADE B
Deep-pocketed investors have adopted a bullish approach towards Starbucks (NASDAQ:SBUX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SBUX usually suggests something big is about to happen. We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Starbucks. This level of activity is out of the ordinary. The general mood among these heavyweight investors is divided, with 75% leaning bullish and 8% bearish. Among these notable options, 5 a
Starbucks's (NYSE:SBUX) short percent of float has risen 12.44% since its last report. The company recently reported that it has 25.61 million shares sold short, which is 2.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
WEST PALM BEACH, Fla., Aug. 13, 2024 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott"), today released the following statement from Elliott Managing Partner Jesse Cohn and Partner Marc Steinberg regarding Starbucks Corporation (NYSE:SBUX) (the "Company" or "Starbucks") and its engagement with the Company: Elliott has become one of the largest investors in Starbucks because of our confidence in the long-term value-creation opportunity we see at one of the world's most important brands. Elliott has been engaged with Starbucks' Board over the past two months regardin
Brian Niccol will join Starbucks on September 9, 2024. Mellody Hobson will be lead independent director. Laxman Narasimhan is stepping down as ceo and as a director effective immediately. Rachel Ruggeri will serve as interim ceo. Starbucks (NASDAQ:SBUX) today announced that Brian Niccol has been appointed chairman and chief executive officer. Niccol will start in his new role on September 9, 2024. Starbucks chief financial officer, Rachel Ruggeri, will serve as interim ceo until that time. Mellody Hobson, Starbucks board chair, will become lead independent director. Niccol currently serves as Chairman and CEO of Chipotle. Since becoming CEO in 2018, Niccol has transformed Chipotle. His